Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year.

ABSTRACT: Strategies for disease control are necessary to reduce incidence of Lyme Disease (LD) including development of safe vaccines for human use. Parainfluenza virus 5 (PIV5) vector has an excellent safety record in animals and PIV5-vectored vaccines are currently under clinical development. We constructed PIV5-vectored LD vaccine candidates expressing OspA from B. burgdorferi (OspA_B31) and a chimeric protein containing sequences from B. burgdorferi and B. afzelii (OspA_BPBPk). Immunogenicity and vaccine efficacy were analyzed in C3H-HeN mice after prime-boost intranasal vaccination with live PIV5-OspA_B31 or PIV5-OspA_BPBPk, subcutaneous (s.c.) vaccination with rOspA_B31+Alum, and the respective controls. Mice vaccinated intranasally with live

SUBMITTER: Gingerich MC 

PROVIDER: S-EPMC10869809 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature